BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19368894)

  • 61. The crystal structure of C2a, the catalytic fragment of classical pathway C3 and C5 convertase of human complement.
    Krishnan V; Xu Y; Macon K; Volanakis JE; Narayana SV
    J Mol Biol; 2007 Mar; 367(1):224-33. PubMed ID: 17234210
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
    Harris CL; Pettigrew DM; Lea SM; Morgan BP
    J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
    Vogel CW; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7707-11. PubMed ID: 6950410
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Preimplantation embryos cooperate with oviductal cells to produce embryotrophic inactivated complement-3b.
    Tse PK; Lee YL; Chow WN; Luk JM; Lee KF; Yeung WS
    Endocrinology; 2008 Mar; 149(3):1268-76. PubMed ID: 18039777
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b.
    Garcia BL; Ramyar KX; Tzekou A; Ricklin D; McWhorter WJ; Lambris JD; Geisbrecht BV
    J Mol Biol; 2010 Sep; 402(1):17-29. PubMed ID: 20654625
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
    Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
    J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
    Rawal N; Pangburn MK
    Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases.
    Qiu WQ; Luo S; Ma SA; Saminathan P; Li H; Gunnersen JM; Gelbard HA; Hammond JW
    Front Immunol; 2021; 12():607641. PubMed ID: 33936031
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
    Daha MR; Kok DJ; Van Es LA
    Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
    McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
    J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cobra venom factor: structural homology with the third component of human complement.
    Vogel CW; Smith CA; Müller-Eberhard HJ
    J Immunol; 1984 Dec; 133(6):3235-41. PubMed ID: 6491285
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.
    Vogt W; Schmidt G; Hinsch B
    Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structural Basis for the Function of Complement Component C4 within the Classical and Lectin Pathways of Complement.
    Mortensen S; Kidmose RT; Petersen SV; Szilágyi Á; Prohászka Z; Andersen GR
    J Immunol; 2015 Jun; 194(11):5488-96. PubMed ID: 25911760
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Purification of native and recombinant cobra venom factor using thiophilic adsorption chromatography.
    Kölln J; Braren I; Bredehorst R; Spillner E
    Protein Pept Lett; 2007; 14(5):475-80. PubMed ID: 17584174
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Formation of high affinity C5 convertase of the classical pathway of complement.
    Rawal N; Pangburn MK
    J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586
    [TBL] [Abstract][Full Text] [Related]  

  • 80. C3 convertases of complement. Molecular genetics, structure and function of the catalytic domains, C2 and B.
    Volanakis JE
    Year Immunol; 1989; 4():218-30. PubMed ID: 2648703
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.